Related Experiment Videos
Insights
Donor and recipient matching significantly improves graft survival, even with cyclosporine (CsA). Combined loci mismatches have a greater impact than individual loci, with Class I antigens (A, B) showing long-term benefits and Class II (DR) showing short-term effects.
Area of Science:
- Transplantation immunology
- Histocompatibility and immunogenetics
Background:
- Donor-recipient matching is crucial for organ transplant success.
- Cyclosporine (CsA) has been a cornerstone of immunosuppression, but its impact on matching efficacy requires further study.
Purpose of the Study:
- To evaluate the impact of human leukocyte antigen (HLA) matching on graft survival in a large cohort of transplant recipients.
- To differentiate the long-term and short-term effects of Class I (A, B) and Class II (DR) mismatches.
Main Methods:
- Analysis of a large dataset of 12,886 patients, with 90% receiving CsA.
- Statistical evaluation of overall survival and graft half-life based on the number of mismatches at A, B, and DR loci.
Main Results:
- Zero mismatches at A, B, and DR loci correlated with a 5% increase in overall survival at 6 months and a 2.5-year increase in half-life.
- Combined loci mismatches demonstrated a more significant impact on graft survival than individual loci.
- Class I mismatches (A, B) had minimal short-term impact but significant long-term effects, while Class II mismatches (DR) showed short-term benefits but less long-term influence.
Conclusions:
- HLA matching remains a critical factor for successful organ transplantation, even in the CsA era.
- A comprehensive matching strategy considering combined loci, particularly Class I antigens, is essential for optimizing long-term graft survival.
Abstract:
1. Matching shows a positive effect, even in the CsA era. In this report we have seen that in a group of 12,886 patients (90% of whom were given CsA), when a donor and recipient had no A,B,DR mismatches, their overall survival exceeded baseline by 5% at 6 months and by a 2.5-year increase in half-life past 6 months. 2. When loci are combined, their effect on graft survival is greater than when loci are viewed individually. Differences from baseline in Figures 6-13 are greater than those in Figures 2-5. 3. Class II DR antigens show a short-term effect but relatively little long-term differences, whereas Class I antigens (A and B loci) have immaterial short-term effects but significant long-term differences. Comparisons involving DR mismatches (eg, Figures 5, 10, 11, 12) always showed significant differences in short-term survival (an average 9% increase from best to worst mismatch categories), but, when DR was studied alone (Fig. 5), small differences in half-lives between 0, 1, and 2 mismatches were noted (ie, 7.6 years vs 6.0 years). In contrast, when A and B mismatches were studied without DR (eg, Figs. 2, 3, 6-9), 6-month graft survivals were never significantly different from baseline, whereas nearly all comparisons (Figs. 2, 3, 6-12) showed significantly widening half-life differences (approximately 4 years) between best and worst mismatch.(ABSTRACT TRUNCATED AT 250 WORDS)